NPC
REGN icon

National Planning Corporation’s Regeneron Pharmaceuticals REGN Stock Holding History

National Planning Corporation’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-542
Closed -$242K – 484
2017
Q3 		$242K Buy
542
+102
+23% +$48.5K 0.02% 579
2017
Q2 		$215K Buy
+440
New +$193K 0.02% 654
2015
Q1 		– Sell
-75
Closed -$30.6K – 1731
2014
Q4 		$30.6K Buy
+75
New +$29.5K ﹤0.01% 1514

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

National Planning Corporation's REGN Position: Q4 2017 in Review

National Planning Corporation sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 542 shares — an estimated $242K sold.

National Planning Corporation first reported a position in REGN in Q4 2014 and held it in 3 quarters. The position peaked at $242K in Q3 2017. 639 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

  • National Planning Corporation reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • National Planning Corporation sold 542 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $242K.
  • National Planning Corporation first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • National Planning Corporation's Regeneron Pharmaceuticals position peaked at $242K in Q3 2017.
  • 639 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.